Treatment of idiopathic nephrotic syndrome with cyclosporine A

Journal of Nephrology

Volumn 10, Issue 1, 1997, Pages 14-24

  Meyrier, Alain ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

adults; children; cyclosporine A; focal segmental glomerulosclerosis; idiopathic nephrotic syndrome; minimal change disease; nephrosis

Indexed keywords

CYCLOSPORIN A;

HUMAN; NEPHROTIC SYNDROME; REVIEW;

CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEPHROTIC SYNDROME; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 0030893345     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Chasis H, Goldring W, Baldwin DS. Effect of febrile plasma, typhoid vaccine and nitrogen mustard on renal manifestations of human glomerulonephritis. Proc Soc Exper Biol and Med 1949; 71: 565.
2. Meyrier A, Simon P, Perret G, Condamin MC. CsA in lipoid nephrosis and focal-segmental hyalinosis rësistant to other treatments. Proceedings of the 18th Annual Meeting of the American Society of Nephrology 1985; 48A (abstract).
3. Tejani A, Butt K, Khawar R, Suthanthiran M, Rosenthal CJ, Trachtman H, et al. Cyclosporine (CYA) induced remission of relapsing nephrotic syndrome (RNS) in children. Proceedings of the 18th Annual Meeting of the American Society of Nephrology 1985; 57A (abstract).
4. Meyrier A. Treatment of glomerular disease with Cyclosporine A. Nephrol Dial Transpl 1989; 4: 923-31.
5. Meyrier A. Focal segmental glomerulosclerosis: to treat or not to treat? Nephrol Dial Transpl 1995; 10: 2355-9.
6. Fuiano G, Comi N, Magri P, Sepe V, Balletta MM, Esposito C, et al. Serial morphometric analysis of sclerotic lesions in primary "focal" segmental glomerulosclerosis. J Am Soc Nephrol 1996; 7: 49-55.
7. Fogo A, Glick AD, Horn SL, Horn RG. Is focal segmental glomerulosclerosis really focal? Distribution of lesions in adults and children. Kidney Int 1995; 47: 1690-6.
8. Pei Y, Cattran D, Delmore T, Katz A, Lang A, Rance P. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Am J Med 1987; 82: 938-44.
9. Korbet S, Schwartz M, Lewis E. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994; 23: 773-83.
10. Korbet SM. Management of idiopathic nephrosis in adults, including steroid-resistant nephrosis. Curr Opin Nephrol Hypertens 1995; 4: 169-76.
11. Burton C, Harris KPG. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996; 27: 765-75.
12. Lagrue G, Branellec A, Niaudet P, Heslan JM, Guillot F, Lang P. Transmission d'un syndrome néphrotique à deux nouveau-nés. Régression spontanée. La Presse Médicale 1991; 20: 255-7.
13. Ali AA, Wilson E, Moorhead JF, Amlot P, Abdulla A, Fernanco ON, et al. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation 1994; 58: 849-51.
14. Robson AM, Giangiacomo J, Kienstra RA, Naqui ST, Ingelfinger JR. Normal glomerular permeability and its modification by minimal change nephrotic syndrome. J Clin Invest 1974; 54: 1190-9.
15. Carrie BJ, Salyer WR, Meyers BD. Minimal change nephropathy: an electrochemical disorder of the glomerular membrane. Am J Med 1981; 70: 262-8.
16. Guasch A, Deen WM, Myers BD. Charge selectivity of the glomerular filtration barrier in healthy and nephrotic humans. J Clin Invest 1993; 92: 2274-82.
17. Levin M, Walters MDS, Smith C, Gascoine P, Barratt TM. Steroid-responsive nephrotic syndrome: a generalized disorder of membrane negative charge. Lancet 1985; ii: 239-42.
18. Boulton-Jones JM, McWilliams G, Chandrachud L. Variation in charge on red cells of patients with different glomerulopathies. Lancet 1986; ii: 186-9.
19. Ota Z, Shikata K, Ota K. Nephrotic tunnels in glomerular basement membrane as revealed by a new electron microscopic method. J Am Soc Nephrol 1994; 4: 1965-73.
20. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T cell function. Lancet 1974; ii: 556-9.
21. Lagrue G, Xheneumont S, Branellec A, Hirbec G, Weil B. A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine 1975; 23: 37-40.
22. Wilkinson AH, Gillespie C, Hartley B, Williams DG. Increase in proteinuria and reduction in number of anionic sites on the glomerular basement membrane in rabbits by infusion of human nephrotic plasma in vivo. Clin Sci 1989; 88: 43-8.
23. Heslan JM, Branellec AI, Laurent J, Lagrue G. The vascular permeability factor is a T lymphocyte product. Nephron 1986; 42: 187-8.
24. Tomizawa S, Nagasawa N, Maruyama K, Shimabukuro N, Arai H, Kuroume T. Release of the vascular permeability factor in minimal change nephrotic syndrome is related to CD4+ lymphocytes. Nephron 1990; 56: 341-2.
25. Tanaka R, Yoshikawa N, Nakamura H, Ito H. Infusion of peripheral blood mononuclear cell products from nephrotic children increases albuminuria in rats. Nephron 1992; 60: 35-41.
26. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991; 40: 453-60.
27. Garin EH, Blanchard DK, Matsushima K, Djeu JY. IL-8 production by peripheral blood mononuclear cells in nephrotic patients. Kidney Int 1994; 45: 1311-7.
28. Verani RR, Hawkins EP. Recurrent focal segmental glomerulosclerosis: a pathological study of the early lesion. Am J Nephrol 1986; 6: 263-70.
29. Zimmerman SW. Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 1984; 22: 32-8.
30. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Yannick J, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330: 7-14.
31. Savin VJ. Mechanisms of proteinuria in noninflammatory glomerular diseases. Am J Kidney Dis 1993; 21: 347-62.
32. Savin VA, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334: 878-83.
33. Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F. Recurrent focal glomerulosclerosis: Natural history and response to therapy. Am J Med 1992; 92: 375-383.
34. Li PKT, MacMoune Lai F, Leung DB, Lui SF, Wang A, Lai KN. Plasma exchange in the treatment of early recurrent focal glomerulosclerosis after renal transplantation. Am J Nephrol 1993; 13: 289-92.
35. Melvin T, Bennett W. Management of nephrotic syndrome in childhood. Drugs 1991; 42: 30-51.
36. Tejani A. Morphological transition in minimal change nephrotic syndrome. Nephron 1985; 39: 157-9.
37. Mendoza SA, Tune BM. Treatment of childhood nephrotic syndrome. J Am Soc Nephrol 1992; 3: 889-94.
38. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 1995; 43: 84-8.
39. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124: 477-84.
40. Meyrier A, Simon P. Treatment of corticoresistant idiopathic nephrotic syndrome in the adult: Minimal change disease and focal segmental glomerulosclerosis. Adv Nephrol 1988; 17: 127-50.
41. Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K. Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis 1991; 17: 687-92.
42. Mak SK, Short CD, Mallick NP. Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transpl 1996; 11: 2192-201.
43. Sherach EM. The effect of cyclosporine A on the immune system. Annu Rev Immunol 1985; 3: 397-423.
44. Tejani A, Ingulli E. Current concepts of pathogenesis of nephrotic syndrome. In: Cyclosporin in the therapy of renal disease. Contrib Nephrol, Berlyne GM and Giovanetti S.editors, Basle: Karger 1995; 114: 1-5.
45. Tejani A, Butt K, Trachtman H, Suthanthiran M, Rosenthal CJ, Khawar R. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int 1988; 33: 729-34.
46. Maruyama K, Tomizawa S, Seki Y, Arai H, Kuroume T. Inhibition of vascular permeability factor production by cyclosporin in minimal change nephrotic syndrome. Nephron 1992; 62: 27-30.
47. Meyrier A. Antiproteinuric and immunologic effects of cyclosporin A in the treatment of glomerular diseases. Nephrol Dial Transpl 1992; 7: 80-4.
48. Jameson MD, Savin VJ, Sharma R, Lovell HB, Diederich DA. Cyclosporine treatment decreases glomerular ultrafiltration coefficient. National Kidney Foundation 19th Scientific Meeting 1989; Abstract A12.
49. Berden JHM, Schrijver G, Assmann KJM, Koene RAP. Antiproteinuric effect of cyclosporin (CsA) in anti-GBM nephritis in the mouse. Proceedings of the 2nd Congress on Immunointervention in Autoimmune Diseases, Paris 1991; 185.
50. Zietse R, Wenting GJ, Kramer P, Schalekamp MADH, Weimar W. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. Clin Sci 1992; 82: 641-50.
51. Zietse R, Derkx FHM, Schalekamp MADH, Weimar W. Cyclosporin and the glomerular filtration barrier in minimal change disease and membranous glomerulopathy. In: A.Tejani, ed, Cyclosporin in the therapy of renal disease. Contrib Nephrol, Berlyne GM and Giovanetti S.editors, Basle: Karger 1995; 114: 6-18.
52. Ambalavanan S, Fauvel JP, Sibley RK, Myers BD. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol 1996; 7: 290-8.
53. Meyrier A, Noël LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 1994; 45: 1446-56.
54. Hoyer PF, Krull F, Brodehl J. CsA in frequently relapsing minimal-change nephrotic syndrome. Lancet 1986; 2: 335.
55. Brodehl J, Brandis M, Heimchen U, Hoyer PF, Burghard R, Ehrich JHH, et al. Cyclosporin A treatment in children with minimal change nephrotic syndrome and focal segmentai glomerulosclerosis. Klin Wochenschr 1988; 66: 1126-37.
56. Capodicasa G, De Santo NG, Nuzzi F, Giordano C. Cyclosporin A in nephrotic syndrome of childhood-A 14 month experience. Int J Pediatr Nephrol 1986; 7: 69-72.
57. Niaudet P, Habib R, Tete MJ, Hinglais N, Broyer M. Cyclosporin in the treatment of idiopathic nephrotic syndrome in children. Pediatric Nephrology 1987; 1: 566-73.
58. Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A. Aggressive, long-term cyclosporine therapy for steroidresistant focal segmental glomerulosclerosis. J Am Soc Nephrol 1995; 5: 1820-5.
59. Niaudet P, French Society of Pediatric Nephrology. Comparison of cyclosporine and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicenter randomized controlled trial. Pediatric Nephrology 1992; 6: 1-3.
60. Niaudet P, Habib R. Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 1994; 5: 1049-56.
61. Tejani A, Suthanthiran M, Pomerantz A. A randomized controlled trial of low-dose prednisone and cyclosporine versus high-dose prednisone in nephrotic syndrome of children. Nephron 1991; 59: 96-9.
62. Ingulli E, Tejani A. Severe hypercholesterolemia inhibits cyclosporin a efficacy in a dose-dependent manner in children with nephrotic syndrome. J Am Soc Nephrol 1992; 3: 254-9.
63. Melocoton TL, Kamil ES, Cohen AH, Fine RN. Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J Kidney Dis 1991; 18: 583-8.
64. Niaudet P, French Society of Pediatric Nephrology. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. J Pediatr 1994; 125: 981-6.
65. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996; 7: 56-63.
66. Niaudet P, Broyer M, Habib R. Serial renal biopsies in children with idiopathic nephrosis receiving cyclosporin. In: Tejani A, ed, Cyclosporin in the Therapy of Renal Disease. Contributions to Nephrology, Berlyne GM and Giovannetti S.editors, Basel: Karger 1995; 114: 78-83.
67. Meyrier A, Niaudet P, Brodehl J. Optimal Use of Sandimmun in Nephrotic Syndrome (monograph). Berlin: Springer-Verlag 1992.
68. Meyrier A. Use of cyclosporine A in the treatment of refractory nephrotic syndrome in adults. Renal Failure 1996; 18: 775-84.
69. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43: 1377-84.
70. Collaborative Study Group of Sandimmun in Nephrotic Syndrome. Safety and tolerability of cyclosporin A: (Sandimmun) in idiopathic nephrotic syndrome. Clin Nephrol 1991; 35 (suppl 1): S48-S60.
71. Meyrier A. Treatment of nephrotic syndrome with cyclosporin A. What remains in 1994? Nephrol Dial Transpl 1994; 9: 596-8.
72. Meyrier A. Use of cyclosporin in the treatment of idiopathic nephrotic syndrome in adults. In: Tejani A, ed, Cyclosporin in the Therapy of Renal Disease. Contributions to Nephrology, Berlyne GM and Giovannetti S.editors, Basel: Karger 1995; 114: 28-48.
73. Habib R, Churg J, Bernstein J, Cameron JS, Cohen AH, Gagnadoux MF, et al. Minimal change disease, mesangial proliferative glomerulonephritis and focal sclerosis: Individual entities or a spectrum of disease? In: Robinson RR, Dennis VW, Ferris TF, Glassock RJ, Kokko JP, and Tisher CC, eds. Nephrology. Proceedings of the IXth International Congress of Nephrology. Anonymous New York: Springer-Verlag 1984; 1: 634-44.
74. Yoshikawa N, Tanaka R, Kitano Y, Nakamura H, Ito H. Long-term cyclosporin in steroid-dependent nephrotic syndrome. In: Tejani A, ed. Cyclosporin in the Therapy of Renal Disease. Contributions to Nephrology, Berlyne GM and Giovannetti S. editors, Basel: Karger 1995; 114: 19-27.
75. Hoyer PF. Complications of cyclosporin therapy. In: Tejani A, ed, Cyclosporin in the Therapy of Renal Disease. Contributions to Nephrology, G.M.Berlyne and Giovannetti S.editors, Basel: Karger 1995; 114: 111-23.
76. Feutren G, Mihatsch MJ. Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. New Engl J Med 1992; 326: 1654-60.